Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Bank of America Corp DE grew its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 220.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 735,940 shares of the company's stock after purchasing an additional 506,576 shares during the period. Bank of America Corp DE owned approximately 0.96% of Kiniksa Pharmaceuticals International worth $35,436,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. EverSource Wealth Advisors LLC increased its holdings in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock worth $25,000 after acquiring an additional 532 shares during the period. Osaic Holdings Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter worth about $31,000. KBC Group NV acquired a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter worth about $34,000. Smartleaf Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $36,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $41,000. Hedge funds and other institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Stock Down 1.4%

Shares of KNSA stock opened at $76.75 on Friday. The company's fifty day simple moving average is $64.42 and its 200-day simple moving average is $53.67. The firm has a market cap of $5.99 billion, a PE ratio of 79.12 and a beta of 0.05. Kiniksa Pharmaceuticals International, plc has a 12 month low of $32.89 and a 12 month high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.30. The company had revenue of $243.60 million during the quarter, compared to analysts' expectations of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. On average, equities analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director G Bradley Cole sold 3,673 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total value of $299,092.39. Following the completion of the sale, the director owned 11,672 shares in the company, valued at $950,450.96. This represents a 23.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 51.98% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on KNSA. Canaccord Genuity Group raised their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. Citigroup increased their price objective on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a "buy (b-)" rating to a "hold (c+)" rating in a report on Thursday. Wedbush boosted their price objective on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 29th. Finally, Zacks Research lowered Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 30th. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $87.38.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source